Connor, Clark & Lunn Investment Management (CC&L)’s Kiniksa Pharmaceuticals KNSA Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $17.3M | Buy |
623,689
+223,946
| +56% | +$6.2M | 0.06% | 271 |
|
|
2025
Q1 | $8.88M | Buy |
399,743
+92,797
| +30% | +$2.06M | 0.04% | 351 |
|
|
2024
Q4 | $6.07M | Sell |
306,946
-17,118
| -5% | -$339K | 0.03% | 437 |
|
|
2024
Q3 | $8.1M | Buy |
324,064
+92,985
| +40% | +$2.32M | 0.04% | 326 |
|
|
2024
Q2 | $4.31M | Sell |
231,079
-30,619
| -12% | -$572K | 0.02% | 457 |
|
|
2024
Q1 | $5.16M | Buy |
261,698
+2,415
| +0.9% | +$47.6K | 0.02% | 425 |
|
|
2023
Q4 | $4.55M | Buy |
259,283
+2,351
| +0.9% | +$41.2K | 0.02% | 450 |
|
|
2023
Q3 | $4.46M | Buy |
256,932
+96,288
| +60% | +$1.67M | 0.02% | 426 |
|
|
2023
Q2 | $2.26M | Buy |
160,644
+120,278
| +298% | +$1.69M | 0.01% | 579 |
|
|
2023
Q1 | $434K | Buy |
40,366
+18,007
| +81% | +$194K | ﹤0.01% | 923 |
|
|
2022
Q4 | $335K | Buy |
+22,359
| New | +$335K | ﹤0.01% | 962 |
|